• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

周围神经病的实验室评估进展。

Advances in the laboratory evaluation of peripheral neuropathies.

机构信息

Intermountain Health Care Neurosciences Center, 5171 South Cottonwood Street, #810, Murray, UT 84107, USA.

出版信息

Curr Neurol Neurosci Rep. 2012 Feb;12(1):84-91. doi: 10.1007/s11910-011-0239-2.

DOI:10.1007/s11910-011-0239-2
PMID:22147264
Abstract

Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy, including the roles of lipid profile, genetic testing, antibody titers, and B(12) testing in a specific dopamine-treated Parkinson's patients. These can serve as recommendations to help guide laboratory testing.

摘要

周围神经病是神经病学中的一个常见临床问题,实验室检测是诊断的一个组成部分。在过去的几年中,已经发表了实践参数来建立基于证据的神经病学检测指南。有许多在实践中常见且被接受的检测方法,但没有明确规定哪些检测是必要的。本文回顾了最近的实践参数出版物以及周围神经病实验室检测的其他更新,包括血脂谱、基因检测、抗体滴度和特定多巴胺治疗的帕金森病患者的 B(12)检测在特定患者中的作用。这些可以作为帮助指导实验室检测的建议。

相似文献

1
Advances in the laboratory evaluation of peripheral neuropathies.周围神经病的实验室评估进展。
Curr Neurol Neurosci Rep. 2012 Feb;12(1):84-91. doi: 10.1007/s11910-011-0239-2.
2
The peripheral neuropathy evaluation in an office-based neurology setting.在神经内科的门诊环境中进行周围神经病变评估。
Semin Neurol. 2011 Feb;31(1):102-14. doi: 10.1055/s-0031-1271305. Epub 2011 Feb 14.
3
Charcot-Marie-Tooth disease and other inherited neuropathies.夏科-马里-图思病及其他遗传性神经病。
Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1208-25. doi: 10.1212/01.CON.0000455885.37169.4c.
4
Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:评估神经病学实践中患者的跌倒风险(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2008 Feb 5;70(6):473-9. doi: 10.1212/01.wnl.0000299085.18976.20.
5
Laboratory evaluation of peripheral neuropathy.周围神经病的实验室评估。
Neurol Clin. 2013 May;31(2):363-76. doi: 10.1016/j.ncl.2013.01.004. Epub 2013 Mar 6.
6
[Peripheral neuropathies: the rational diagnostic process].[周围神经病变:合理的诊断流程]
Rev Med Interne. 2006 Apr;27(4):302-12. doi: 10.1016/j.revmed.2005.10.018. Epub 2005 Dec 7.
7
Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.实践参数:远端对称性多发性神经病的评估:实验室检查和基因检测的作用(循证综述)。美国神经病学学会、美国神经肌肉与电诊断医学协会以及美国物理医学与康复学会报告。
Neurology. 2009 Jan 13;72(2):185-92. doi: 10.1212/01.wnl.0000336370.51010.a1. Epub 2008 Dec 3.
8
Laboratory Tests for Neuropathies: What to do and to Avoid.神经病变的实验室检查:该做什么和该避免什么。
J Neuromuscul Dis. 2020;7(3):279-286. doi: 10.3233/JND-200488.
9
Test Utilization and Value in the Evaluation of Peripheral Neuropathies.神经病变评估中的检测应用和价值。
Continuum (Minneap Minn). 2020 Oct;26(5):1384-1391. doi: 10.1212/CON.0000000000000910.
10
Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review).远端对称性多发性神经病的评估:实验室检查和基因检测的作用(循证综述)
Muscle Nerve. 2009 Jan;39(1):116-25. doi: 10.1002/mus.21226.

引用本文的文献

1
What is the Next Step after an Electrodiagnostic Study in Children with Polyneuropathies? Rationale for Laboratory and Other Diagnostic Tests.患有多发性神经病的儿童进行电诊断研究后下一步该怎么做?实验室检查及其他诊断测试的基本原理。
Iran J Child Neurol. 2023 Fall;17(4):9-22. doi: 10.22037/ijcn.v17i4.43124. Epub 2023 Oct 26.

本文引用的文献

1
MFN2 mutations cause severe phenotypes in most patients with CMT2A.MFN2 突变导致 CMT2A 患者的大多数表现出严重的表型。
Neurology. 2011 May 17;76(20):1690-6. doi: 10.1212/WNL.0b013e31821a441e. Epub 2011 Apr 20.
2
Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy.抗 CRMP5 抗体相关脱髓鞘性神经病先于乳腺癌诊断:癌症治疗后预后良好。
Muscle Nerve. 2011 May;43(5):764-6. doi: 10.1002/mus.22036.
3
A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood.
儿童 X 连锁遗传性运动感觉神经病的回顾性研究。
Neurology. 2011 Feb 1;76(5):461-6. doi: 10.1212/WNL.0b013e31820a0ceb.
4
Charcot-Marie-Tooth disease subtypes and genetic testing strategies.Charcot-Marie-Tooth 病亚型与基因检测策略。
Ann Neurol. 2011 Jan;69(1):22-33. doi: 10.1002/ana.22166.
5
Four novel cases of periaxin-related neuropathy and review of the literature.四种新型周围神经髓鞘蛋白 22 相关神经病病例及文献复习
Neurology. 2010 Nov 16;75(20):1830-8. doi: 10.1212/WNL.0b013e3181fd6314.
6
Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features.多灶性运动神经病:抗 GM1 IgM 抗体与临床特征的关联。
Neurology. 2010 Nov 30;75(22):1961-7. doi: 10.1212/WNL.0b013e3181ff94c2. Epub 2010 Oct 20.
7
Laboratory evaluation of peripheral neuropathy.周围神经病的实验室评估。
Semin Neurol. 2010 Sep;30(4):337-49. doi: 10.1055/s-0030-1267277. Epub 2010 Oct 12.
8
Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy.多潘立酮治疗下的帕金森病伴钴胺素和维生素 B6 缺乏的亚急性轴索性神经病。
Mov Disord. 2010 Aug 15;25(11):1748-52. doi: 10.1002/mds.23342.
9
Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy.抗 SOX1 抗体在副肿瘤性和非副肿瘤性神经病患者中的表达。
J Neuroimmunol. 2010 Sep 14;226(1-2):177-80. doi: 10.1016/j.jneuroim.2010.07.005. Epub 2010 Aug 11.
10
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.左旋多巴、甲基丙二酸和特发性帕金森病的神经病变。
Ann Neurol. 2010 Jul;68(1):28-36. doi: 10.1002/ana.22021.